Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.dsx.2020.06.027 http://scihub22266oqcxt.onion/10.1016/j.dsx.2020.06.027 32590335!7301810!32590335     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Metab+Syndr 2020 ; 14 (5): 929-931 Nephropedia Template TP {{tp|p=32590335|t=2020. Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19 |pdf=|usr=}}{{32590335}} gab.com Text Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19 JO: Diabetes Metab Syndr http://www.kidney.de/pget.php?&tw=1&pmid=32590335 #FOAvip BACKGROUND AND AIMS: Cardiac biomarkers like cardiac troponins and natriuretic peptides are elevated in a substantial proportion of patients with coronavirus disease 2019 (COVID-19). We propose an algorithmic approach using cardiac biomarkers to triage, risk-stratify and prognosticate patients with severe COVID-19. METHODS: We systematically searched the PubMed and Google Scholar databases until May 31st, 2020, and accessed the available data on the role of cardiac biomarkers in patients with COVID-19. RESULTS: COVID-19 is associated with acute cardiac injury in around 7-28% of patients, significantly increasing its associated complications and mortality. Patients with underlying cardiovascular disease are more prone to develop acute cardiac injury as a result of COVID-19. The use of cardiac biomarkers may aid in differentiating the cardiac cause of dyspnea in patients with severe COVID-19. Cardiac biomarkers may also aid in triaging, risk-stratification, clinical decision-making, and prognostication of patients with COVID-19. However, there are concerns that routine testing in all patients with COVID-19 irrespective of severity, may result in unnecessary downstream investigations which may be misleading. In this brief review, using an algorithmic approach, we have tried to rationalize the use of cardiac biomarkers among patients with severe COVID-19. This approach is also likely to lessen the infection exposure risk to the cardiovascular team attending patients with severe COVID-19. CONCLUSION: It appears beneficial to triage, risk-stratify, and prognosticate patients with COVID-19 based on the evidence of myocardial injury and the presence of underlying cardiovascular disease. Future research studies are, however, needed to validate these proposed benefits. Twit Text FOAVip Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19 ????Diabetes Metab Syndr http://www.kidney.de/pget.php?&tw=1&pmid=32590335 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32590335 #FOAvip English Wikipedia <ref>{{Cite pmid|32590335}}</ref> Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19 #MMPMID32590335 Mahajan K; Chand Negi P; Ganju N; Asotra S Diabetes Metab Syndr 2020[Sep]; 14 (5): 929-931 PMID32590335show ga BACKGROUND AND AIMS: Cardiac biomarkers like cardiac troponins and natriuretic peptides are elevated in a substantial proportion of patients with coronavirus disease 2019 (COVID-19). We propose an algorithmic approach using cardiac biomarkers to triage, risk-stratify and prognosticate patients with severe COVID-19. METHODS: We systematically searched the PubMed and Google Scholar databases until May 31st, 2020, and accessed the available data on the role of cardiac biomarkers in patients with COVID-19. RESULTS: COVID-19 is associated with acute cardiac injury in around 7-28% of patients, significantly increasing its associated complications and mortality. Patients with underlying cardiovascular disease are more prone to develop acute cardiac injury as a result of COVID-19. The use of cardiac biomarkers may aid in differentiating the cardiac cause of dyspnea in patients with severe COVID-19. Cardiac biomarkers may also aid in triaging, risk-stratification, clinical decision-making, and prognostication of patients with COVID-19. However, there are concerns that routine testing in all patients with COVID-19 irrespective of severity, may result in unnecessary downstream investigations which may be misleading. In this brief review, using an algorithmic approach, we have tried to rationalize the use of cardiac biomarkers among patients with severe COVID-19. This approach is also likely to lessen the infection exposure risk to the cardiovascular team attending patients with severe COVID-19. CONCLUSION: It appears beneficial to triage, risk-stratify, and prognosticate patients with COVID-19 based on the evidence of myocardial injury and the presence of underlying cardiovascular disease. Future research studies are, however, needed to validate these proposed benefits. |*Algorithms[MESH] |Betacoronavirus/*isolation & purification[MESH] |Biomarkers/*analysis[MESH] |COVID-19[MESH] |Cardiovascular Diseases/*diagnosis/epidemiology/virology[MESH] |Coronavirus Infections/*complications/epidemiology/virology[MESH] |Humans[MESH] |India/epidemiology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*complications/epidemiology/virology[MESH] |Prognosis[MESH] |Risk Assessment/*methods[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Cardiac biomarker-based risk stratification algorithm in patients with(epmc).pdf DeepDyve Pubget Overpricing